Search Results

There are 9933 results for: content related to: Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding

  1. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  2. Adverse effects of biologics: a network meta-analysis and Cochrane overview

    Overview of Reviews

    The Cochrane Library

    Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara J Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian K Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Chris Cameron, Michael PT Lunn, Peter Tugwell and Rachelle Buchbinder

    Published Online : 16 FEB 2011, DOI: 10.1002/14651858.CD008794.pub2

  3. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    Brian W Behm and Stephen J Bickston

    Published Online : 23 JAN 2008, DOI: 10.1002/14651858.CD006893

  4. You have free access to this content
    Practical application of anti-TNF therapy for luminal Crohn's disease

    Inflammatory Bowel Diseases

    Volume 17, Issue 11, November 2011, Pages: 2366–2391, Michael A. Kamm, Siew C. Ng, Peter De Cruz, Patrick Allen and Stephen B. Hanauer

    Version of Record online : 18 FEB 2011, DOI: 10.1002/ibd.21655

  5. You have free access to this content
    Certolizumab pegol (CDP870) for rheumatoid arthritis in adults

    Intervention Review

    The Cochrane Library

    Vicente Ruiz Garcia, Paresh Jobanputra, Amanda Burls, Juan B Cabello, Paloma Vela Casasempere, Sylvia Bort-Marti and Francis JB Kynaston-Pearson

    Published Online : 18 SEP 2014, DOI: 10.1002/14651858.CD007649.pub3

  6. You have free access to this content
    Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn’s disease

    Alimentary Pharmacology & Therapeutics

    Volume 29, Issue 6, March 2009, Pages: 605–614, L.-M. SHAO, M.-Y. CHEN, Q.-Y. CHEN and J.-T. CAI

    Version of Record online : 13 JAN 2009, DOI: 10.1111/j.1365-2036.2009.03929.x

  7. Abstracts from the 2012 Advances in Inflammatory Bowel Diseases Crohn's & Colitis Foundation's National Clinical & Research Conference December 13–15, 2012 Hollywood, Florida

    Inflammatory Bowel Diseases

    Volume 18, Issue S1, December 2012, Pages: S1–S127,

    Version of Record online : 15 NOV 2012, DOI: 10.1002/ibd.23058

  8. Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 4, April 2012, Pages: 635–646, I Ordás, D R Mould, B G Feagan and W J Sandborn

    Version of Record online : 22 FEB 2012, DOI: 10.1038/clpt.2011.328

  9. You have free access to this content
    Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab

    Journal of Digestive Diseases

    Volume 12, Issue 5, October 2011, Pages: 379–383, Himanshu Dev VERMA, Ellen Janice SCHERL, Vinita Elizabeth JACOB and Brian Paul BOSWORTH

    Version of Record online : 29 SEP 2011, DOI: 10.1111/j.1751-2980.2011.00522.x

  10. Targeted Treatments for Inflammatory Bowel Diseases

    Inflammatory Bowel Disease: Translating basic science into clinical practice

    Finbar MacCarthy, Laurence J. Egan, Pages: 360–391, 2010

    Published Online : 18 MAY 2010, DOI: 10.1002/9781444318418.ch25

  11. Abstracts from the 2007 CCFA National Research and Clinical Conference, 6th Annual Advances in the Inflammatory Bowel Diseases

    Inflammatory Bowel Diseases

    Volume 14, Issue S1, January 2008, Pages: S1–S39,

    Version of Record online : 10 DEC 2007, DOI: 10.1002/ibd.20360

  12. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents

    Inflammatory Bowel Diseases

    Volume 13, Issue 11, November 2007, Pages: 1323–1332, Andrew Nesbitt, Gianluca Fossati, Marianne Bergin, Paul Stephens, Sue Stephens, Roly Foulkes, Derek Brown, Martyn Robinson and Tim Bourne

    Version of Record online : 16 JUL 2007, DOI: 10.1002/ibd.20225

  13. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis

    Overview of Reviews

    The Cochrane Library

    Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Ahmed Kotb, Robin Christensen, Amy S Mudano, Lara J Maxwell, Nipam P Shah, Peter Tugwell and George A Wells

    Published Online : 13 MAY 2016, DOI: 10.1002/14651858.CD012183

  14. You have free access to this content
    Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

    Alimentary Pharmacology & Therapeutics

    Volume 33, Issue 5, March 2011, Pages: 541–550, B. G. Feagan, W. J. Sandborn, D. C. Wolf, G. Coteur, O. Purcaru, Y. Brabant and P. J. Rutgeerts

    Version of Record online : 12 JAN 2011, DOI: 10.1111/j.1365-2036.2010.04568.x

  15. Abstracts from the 2006 CCFA National Research and Clinical Conference, 5th Annual Advances in the Inflammatory Bowel Diseases, Dec. 1-3, 2006, Miami, FL

    Inflammatory Bowel Diseases

    Volume 13, Issue S5, May 2007, Pages: 643–674,

    Version of Record online : 6 APR 2007, DOI: 10.1002/ibd.20147

  16. You have free access to this content
    When to use biological agents in inflammatory bowel disease

    Journal of Gastroenterology and Hepatology

    Volume 27, Issue 7, July 2012, Pages: 1141–1149, Crispin Corte, Payal Saxena, Stephen Tattersall, Christian Selinger and Rupert W Leong

    Version of Record online : 19 JUN 2012, DOI: 10.1111/j.1440-1746.2011.07056.x

  17. Positioning biologic agents in the treatment of Crohn's disease

    Inflammatory Bowel Diseases

    Volume 15, Issue 10, October 2009, Pages: 1570–1582, Stephen B. Hanauer

    Version of Record online : 23 MAR 2009, DOI: 10.1002/ibd.20918

  18. Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 6, June 2012, Pages: 515–526, Derek H. Tang, Edward P. Armstrong and Jeannie K. Lee

    Version of Record online : 23 APR 2012, DOI: 10.1002/j.1875-9114.2011.01053.x

  19. You have free access to this content
    Use of biological molecules in the treatment of inflammatory bowel disease

    Journal of Internal Medicine

    Volume 270, Issue 1, July 2011, Pages: 15–28, O. H. Nielsen, J. B. Seidelin, L. K. Munck and G. Rogler

    Version of Record online : 1 MAR 2011, DOI: 10.1111/j.1365-2796.2011.02344.x

  20. Abstracts from the 2008 Advances in Inflammatory Bowel Diseases, Crohn's & Colitis Foundation's National Clinical & Research Conference

    Inflammatory Bowel Diseases

    Volume 14, Issue S3, December 2008, Pages: S1–S49,

    Version of Record online : 26 NOV 2008, DOI: 10.1002/ibd.20829